Since the LDLR is differentially expressed in organs and is overexpressed in many cancers [24,29,41,42], the present work opens new opportunities and warrants further evaluation for oligonucleotide delivery to different organs or in tumors that otherwise do not support functional uptake of naked oligonucleotides. The gene discussed is LDLR; the disease is cancer.